THERAPY DOSSIER · th-878ab5feaf87

Xin-Ji-Er-Kang (Chinese herbal formulation)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31228798 ↗2019Reported benefit

Xin-Ji-Er-Kang ameliorates kidney injury following myocardial infarction by inhibiting oxidative stress via Nrf2/HO-1 pathway in rats.

RatIschaemia-reperfusionCardiacSprague-Dawleyn = 138 Sprague-Dawley rats in total; control n=8, sham, myocar…Started after myocardial infarction

Model: Surgical myocardial infarction with secondary kidney injury

Xin-Ji-Er-Kang improved renal hypertrophy index, blood urea nitrogen and cystatin C, limited scar formation and improved cardiac function, sustained Nrf2 nuclear translocation and HO-1 expression, and lowered oxidative stress and renin-angiotensin-aldosterone markers relative to untreated infarctio…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…